<em>MTHFR C677T</em>基因多态性与晚期非小细胞肺癌化疗不良反应的关系

寇军燕; 洪卫; 洪丹; 苏丹; 娄广媛; 张沂平

doi:10.3969/j.issn.1007-3969.2014.03.007

您当前的位置：

首页 >

文章列表页 >

MTHFR C677T基因多态性与晚期非小细胞肺癌化疗不良反应的关系

更新时间：2025-12-31

- MTHFR C677T基因多态性与晚期非小细胞肺癌化疗不良反应的关系
- Relationship between MTHFR C677T gene polymorphisms and chemotherapy side effects in advanced non-small cell lung cancer
- 中国癌症杂志 2014年24卷第3期页码：197-202
- 作者机构：
  
  1. 杭州市肿瘤医院肿瘤综合科,浙江,杭州
  2. 浙江省肿瘤医院化疗中心十六病区,浙江,杭州
- 作者简介：
- 基金信息：
  
  浙江省医药卫生科学研究基金计划项目(No：2007B025)
- DOI：10.3969/j.issn.1007-3969.2014.03.007
  中图分类号：
- 网络出版：2014-04-01，
  
  纸质出版：2014-04-01
- 稿件说明：
移动端阅览
寇军燕,洪卫,洪丹,苏丹,娄广媛,张沂平.

寇军燕, 洪卫, 洪丹, et al. Relationship between MTHFR C677T gene polymorphisms and chemotherapy side effects in advanced non-small cell lung cancer[J]. China Oncology, 2014, 24(3): 197-202.
寇军燕,洪卫,洪丹,苏丹,娄广媛,张沂平. DOI： 10.3969/j.issn.1007-3969.2014.03.007.

寇军燕, 洪卫, 洪丹, et al. Relationship between MTHFR C677T gene polymorphisms and chemotherapy side effects in advanced non-small cell lung cancer[J]. China Oncology, 2014, 24(3): 197-202. DOI： 10.3969/j.issn.1007-3969.2014.03.007.

摘要

背景与目的：亚甲基四氢叶酸还原酶(methylene tetrahydrofolate reductase，MTHFR)是叶酸代谢的关键酶，在DNA甲基化中起重要作用。本研究旨在探讨MTHFR C677T多态性与晚期非小细胞肺癌(nonsmall cell lung cancer，NSCLC)化疗不良反应的关系。方法：收集2007年6月—2009年5月在浙江省肿瘤医院经病理学确诊的晚期NSCLC患者100例。所有患者均接受铂类药物联合吉西他滨的方案化疗。用等位基因特异-PCR技术检测患者MTHFR基因型。结果：100例晚期NSCLC患者中，MTHFR C677T T/T、T/C和C/C基因型频率分别为20%、44%和36%。在血液学不良反应中，C/C基因型血小板减少发生率较T/T、T/C基因型低，差异有统计学意义(P=0.039)。本研究未发现MTHFR各基因型与化疗后恶心、呕吐不良反应相关。结论：MTHFRC677T基因多态性对预测晚期NSCLC含铂类药物方案化疗后不良反应有临床意义。

Abstract

Background and purpose: Methylene tetrahydrofolate reductase (MTHFR) plays an important role in metabolism of folate and DNA methylation. This study aimed to investigate the relationship between methylene tetrahydrofolate reductase (MTHFR) C677T polymorphism and chemotherapy side effects in advanced non-small cell lung cancer (NSCLC) patients. Methods: A total of 100 patients with advanced NSCLC confirmed by pathology were included into this study in Zhejiang Cancer Hospital from Jun. 2007 to May. 2009. All patients received the combined chemotherapy of platinum drug and gemcitabine. MTHFR genotypes were determined by allele-specific-PCR technology. Results: In the 100 cases

genotype frequency of MTHFR C677T T/T

T/C and C/C were 20%

44% and 36%

respectively. Compared with patients of T/T and T/C genotype

patients of C/C genotype were correlated with decreased rate of thrombocytopenia to chemotherapy (P=0.039). No significant differences were observed concerning gastrointestinal toxicity. Conclusion: MTHFR C677T gene polymorphism can be used to predict the adverse reactions to platinum-based chemotherapy in patients with advanced NSCLC.

关键词

Keywords

references

浏览量

2603

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

止吐用低频电刺激仪防治非小细胞肺癌患者化疗导致恶心呕吐的回顾性研究

BIM联合Scribble预测晚期非小细胞肺癌化疗效果

EGFR-TKI联合化疗治疗EGFR-TKI获得性耐药的晚期非小细胞肺癌疗效分析

化疗相关腹泻全程管理中国专家共识（2025年版）

卡瑞利珠单抗联合化疗及靶向治疗在复发、转移及初治晚期宫颈癌中的疗效与安全性分析：一项回顾性队列研究

MTHFR C677T基因多态性与晚期非小细胞肺癌化疗不良反应的关系

Relationship between MTHFR C677T gene polymorphisms and chemotherapy side effects in advanced non-small cell lung cancer

DOI：10.3969/j.issn.1007-3969.2014.03.007

摘要

Abstract

关键词

Keywords

references